N/A
N=3,923
Effectiveness and Implementation of eScreening in Post 9/11 Transition Programs
Depression · Stress Disorders, Post-Traumatic · Suicide
Bottom Line
View on ClinicalTrials.gov: NCT04506164 ↗Enrolled (actual)
3,923
Serious AEs
—
Results posted
Feb 2026
Primary outcome: Primary: Compare Rate of PTSD Screening During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation — 724; 1408; 893 Participants — p=<.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- eScreening (Other); Screening As Usual (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Dec 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Compare Rate of PTSD Screening During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
724; 1408; 893 | <.001 sig |
| PRIMARY Compare Rate of Depression (PHQ-2) Screening During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
744; 1433; 905 | <.001 sig |
| PRIMARY Compare Rate of Alcohol Screening (AUDIT) During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
761; 1494; 929 | <.001 sig |
| PRIMARY Compare Rate of Suicide Screening (CSSRS) During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
831; 1588; 989 | <.001 sig |
| PRIMARY Time to PTSD Screening (PC-PTSD-5) Completion During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
27.90; 27.94; 27.74 | <.001 sig |
| PRIMARY Time to Depression (PHQ-2) Screening Completion During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
27.83; 27.88; 27.70 | <.001 sig |
| PRIMARY Time to Alcohol Screening (AUDIT) Completion During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
27.78; 27.74; 27.56 | <.001 sig |
| PRIMARY Time to Suicide Screening (CSSRS) Completion During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
27.30; 27.30; 27.02 | <.001 sig |
| PRIMARY Change in Rate of Referral to Mental Health Care Following Positive PTSD Screen (PC-PTSD-5) During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation. |
31; 32; 34 | .257 |
| PRIMARY Change in Rate of Referral to Mental Health Care Following Positive Depression Screen (PHQ-2) During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
31; 28; 27 | .846 |
| PRIMARY Change in Rate of Referral to Substance Use Treatment Following Positive Alcohol Screen (AUDIT) During eScreening Implementation and Sustainment vs. Screening as Usual/Pre-implementation |
5; 10; 7 | .450 |
| SECONDARY PRISM Contextual Survey Instrument (PCSI) |
3.8; 4.2; 3.9 | .057 |
Summary
Electronic screening is effective for timely detection of, and intervention for, suicidal ideation and other mental health symptoms. The VA eScreening program is a patient self-report electronic screening system that has shown promise for the efficient and effective collection of mental and physical health information among Veterans. However, additional effectiveness and implementation research is warranted to evaluate the impact of eScreening within VHA. This study addresses questions of the impact of eScreening compared to screening as usual, while evaluating a multi-component implementation strategy (MCIS) for optimal enterprise rollout of eScreening in VA Transition Care Management clinics.
Eligibility Criteria
Inclusion Criteria
Staff inclusion criteria:
- Direct or indirect involvement with implementation of eScreening at the site
- Capable of informed consent
Exclusion Criteria
Staff exclusion criteria:
- Not involved in or directly impacted by eScreening involvement at each site
Data sourced from ClinicalTrials.gov (NCT04506164). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.